3 min read · Last reviewed: July 2026 · European Cannabis Institute Editorial Team

Cannabis Product Specifications

Development of release and shelf-life specifications for cannabis flower, oils, extracts and finished dosage forms.

Overview. A specification is a justified set of tests, methods and acceptance criteria used to determine whether a material or product is suitable for its intended use. Cannabis specifications should reflect product type, manufacturing process, route of administration and patient exposure.

From quality target to specification

The process starts with the quality target product profile and critical quality attributes. Tests should be selected because they control a relevant risk, not simply because they appear on a competitor certificate of analysis.

Starting-material specifications

Cannabis starting materials may require botanical identity, cannabinoid profile, moisture, microbiology, pesticides, mycotoxins, elemental impurities and foreign matter. The specification should distinguish agricultural controls from pharmaceutical release controls.

Intermediate specifications

Extracts and bulk oils may require assay, related substances, residual solvents, appearance, density or viscosity. Intermediate limits can support process control and prevent unsuitable material progressing.

Finished-product specifications

Flower products may include identity, assay, cannabinoid profile, water activity, microbiology and contaminants. Oils and capsules may require uniformity, dissolution, fill volume, impurities and packaging-related attributes.

Release versus shelf-life criteria

A product may need tighter release criteria to ensure it remains within shelf-life limits. Stability data should support the relationship between the two.

Method capability and uncertainty

Acceptance criteria should not be set closer than the method can reliably distinguish. Reporting limits, precision and measurement uncertainty should be considered.

Trend limits and internal controls

Internal alert limits may detect deterioration before formal specification failure. These limits should support process understanding rather than replace registered specifications.

Practical reference table

ProductTypical release testsPotential shelf-life focus
Dried flowerIdentity, assay, water activity, microbiology, contaminantsCannabinoid change, moisture and CBN trend
OilAssay, appearance, impurities, fill volumeOxidation, precipitation and container interaction
ExtractAssay, residual solvent, impurity profileChemical degradation and solvent trend
CapsuleAssay, uniformity, dissolution, microbiologyDissolution, shell integrity and assay
SprayAssay, delivered dose, microbial qualityDelivered-dose and in-use performance

Control and decision path

Define product quality target
Identify critical quality attributes
Select tests and methods
Set justified criteria
Confirm with development/stability data
Approve and maintain
ECI editorial perspective. The strongest cannabis quality systems connect method, sampling and specification decisions to the real product matrix. Generic acceptance criteria, copied sampling plans or vendor procedures create false confidence when they are not demonstrated to work for the site's flower, oil, extract or dosage form.

Frequently asked questions

Can specifications be copied from another product?

No. They must be justified for the specific product, process and market.

What is the difference between release and shelf-life specifications?

Release criteria apply at batch release; shelf-life criteria apply throughout storage.

Should every cannabinoid have a release limit?

Only where its control is scientifically and regulatorily justified.

What is an internal alert limit?

A company-defined threshold used to detect deterioration before a formal specification is exceeded.

How does method capability affect specification setting?

The method must reliably distinguish compliant from non-compliant results around the limit.

Primary references and guidance

  1. ICH Q6A, Specifications
  2. ICH Q8(R2)
  3. ICH Q9(R1)
  4. EU GMP Part I, Chapter 6
  5. European Pharmacopoeia, Cannabis flower
  6. EMA cannabis-derived medicinal product guidance
  7. ICH Q1A(R2)
  8. USP General Notices

Confirm the current effective revision and national applicability before operational or regulatory use.

Related ECI reading

Related reading

Article
Endotoxin Testing for Cannabis-Derived Products
Article
TOC Monitoring for Pharmaceutical Water
Article
Mycotoxin Testing in Cannabis
Article
Analytical Method Transfer for Cannabis Testing
Article
Cannabis Laboratory Investigations